SEC Company Response from Outlook Therapeutics, (OTLK) — Apr 5, 2019
Outlook Therapeutics, Inc.
Date: April 5, 2019 · CIK: 0001649989 · Accession: 0001144204-19-018389
AI Filing Summary & Sentiment
File numbers found in text: 333-229761
Letter
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
Via EDGAR
April 5, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeff Gabor
Re: Outlook Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-229761
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on April 2, 2019, in which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-229761) (the “Registration Statement”) to April 4, 2019 at 5:00 p.m., Eastern Time (which was later changed orally to April 5, 2019 at 5:00 p.m., Eastern Time), in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date thereof.
Very truly yours,
Outlook Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
Via
EDGAR
April 5, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeff Gabor
Re: Outlook Therapeutics, Inc.
Registration
Statement on Form S-1
File No. 333-229761
Ladies and Gentlemen:
Reference
is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on April 2, 2019, in
which we requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No.
333-229761) (the “Registration Statement”) to April 4, 2019 at 5:00 p.m., Eastern Time (which was later
changed orally to April 5, 2019 at 5:00 p.m., Eastern Time), in accordance with Rule 461 under the Securities Act of 1933, as
amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally
withdraw our request for acceleration of the effective date thereof.
Very truly yours,
Outlook Therapeutics, Inc.
By:
/s/ Lawrence A. Kenyon
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
cc: Yvan-Claude Pierre, Cooley LLP
Marianne
Sarrazin, Cooley LLP
Pia Kaur, Cooley LLP
T: 609.619.3990 | W: www.outlooktherapeutics.com | E: info@outlooktherapeutics.com